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Adult T cell leukaemia/lymphoma (ATL) is a predomi-
nantly CD4+ T cell neoplasia caused by human T cell
lymphotropic Virus 1 (HTLV-1) infection. A few cases of
CD8+ ATL have been reported but its existence has been
debated. An Afrocaribbean female presented to the der-
matology clinic with widespread papulo-nodular rash.
HTLV-1 infection was detected by serology. Skin biopsy
showed dense dermal infiltration by mainly CD8+ T cells
which also expressed CD2, CD3, CD5, CD7 and occa-
sionally CD25. Further investigations showed a mild lym-
phocytosis (4.4 x 106/L), circulating flower cells, absolute
CD4+ count 1247 x 106/L (28.3% of lymphocytes), abso-
lute CD8+ count x 2617 x 106/L (59.8% of lymphocytes),
LDH 241 U/L (NR 135 – 214), Calcium 2.7 mmol/L (NR
2.2 – 2.6) but with increased serum PTH level. HTLV-1
proviral load (PVL) in peripheral blood mononuclear
cells was 46%. PET/CT scan demonstrated FDG avid
lymph nodes above and below the diaphragm. Axillary
lymph node core biopsy showed CD20+ B cells nodules
admixed with mainly small-to-medium sized T cells and
a small population of large T cells. The small lympho-
cytes were mainly CD8+ T cells (also expressed CD2,
CD3, CD5, and CD7 whereas the large cells expressed
CD8, CD25 and CD30. Fewer than 5% expressed Ki67
(MIB-1). TCR clonality studies by PCR revealed expan-
sion of an identical clone in all three compartments
(skin, lymph node and blood). Detailed immunopheno-
typing on peripheral blood demonstrated a single domi-
nant TCR vb1+ clone (>90% of total CD8 T cells) which
was CD3+, CD7+, CCR4+, CD25 low and, TSCL-1-. In
summary we report a malignant CD8+ clone with atypical
immunophenotype in a patient with high PVL. To confirm
a working diagnosis of CD8+ ATL high throughput
sequencing of each proviral integration sites is underway.
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